<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00410410</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-108</org_study_id>
    <nct_id>NCT00410410</nct_id>
  </id_info>
  <brief_title>A Study of Abatacept in Patients With Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if abatacept can improve signs and
      symptoms of active ulcerative colitis in patients who have not had an adequate response to
      other therapies. The safety of this treatment will also be studied
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Induction Period First Cohort (IP1C) arms (30/10 mg/kg and 10 mg/kg) were
      placebo-controlled arms that were used for the primary endpoint and its analysis. The
      Induction Period Second Cohort arms (IP2C 30/10 mg/kg and 10 mg/kg) were not
      placebo-controlled, their sole purpose being to provide sufficient numbers of participants
      for the maintenance phase. The first cohort (IP1C) was randomized to receive placebo or 1 of
      3 doses of abatacept. Following completion of the IP1C randomization, a second cohort (IP2C)
      was randomized to receive 1 of 2 doses of abatacept. After all participants in the IP1C
      completed or discontinued, the data was locked and the formal analysis for the Induction
      Period primary endpoint was performed. Summary tables for the second cohort (IP2C) and the
      Maintenance and Open-label phases were generated from a second, subsequent data lock.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12</measure>
    <time_frame>Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation</measure>
    <time_frame>Day OL-1 through the end of the OL</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With AEs of Special Interest</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Physical Examination Findings</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Marked Hematology Laboratory Abnormalities</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; calcium (Ca): &lt;0.8 x LLN/&gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN/ &gt;1.5 x ULN; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IP; Baseline Mayo Score: IP1C</measure>
    <time_frame>Baseline</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C</measure>
    <time_frame>Baseline</time_frame>
    <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C</measure>
    <time_frame>Baseline (Day IP-1), Day IP-85 (Week 12)</time_frame>
    <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</measure>
    <time_frame>Day IP-85 (Week 12)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</measure>
    <time_frame>Day IP-85 (Week 12)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</measure>
    <time_frame>Day IP-85 (Week 12)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance
=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</measure>
    <time_frame>Week 12 (Day IP-85)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Physical Examination Findings: IP1C + IP2C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; Sodium (Na): &lt;0.95 x LLN/ &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; calcium (Ca): &lt;0.8 x LLN/&gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; Sodium (Na): &lt;0.95 x LLN/ &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C</measure>
    <time_frame>Day IP-1 through Day IP-85</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C</measure>
    <time_frame>For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85). For participants treated in OL directly after IP: Day IP-1 to Day OL-1. For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)</time_frame>
    <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants in Clinical Remission at Month 12</measure>
    <time_frame>Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12</measure>
    <time_frame>Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12</measure>
    <time_frame>Month 6 (Day MP-169), Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12</measure>
    <time_frame>Day MP-365 (Month 12)</time_frame>
    <description>Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Mean Change From Baseline to Month 12 in IBDQ</measure>
    <time_frame>Day MP-365</time_frame>
    <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)</measure>
    <time_frame>Day MP-365</time_frame>
    <description>The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12</measure>
    <time_frame>Day MP-365 (Month 12)</time_frame>
    <description>Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Month 12</measure>
    <time_frame>Day MP-365 (Month 12)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Month 12</measure>
    <time_frame>Day MP-365 (Month 12)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (≤1 Point) at Month 12</measure>
    <time_frame>Day MP-365 (Month 12)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</measure>
    <time_frame>Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</measure>
    <time_frame>Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</measure>
    <time_frame>Month 12 (Day MP-365)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Abatacept-Induced Antibodies</measure>
    <time_frame>For participants not entering OL: All measurements starting after Day MP-1 (including follow-up visits). For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1).</time_frame>
    <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation</measure>
    <time_frame>Day MP-1 through Day MP-365</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With AEs of Special Interest</measure>
    <time_frame>Day MP-1 through Day MP-365</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Physical Examination Findings</measure>
    <time_frame>Day IP-85 through Day MP-365</time_frame>
    <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Marked Hematology Laboratory Abnormalities</measure>
    <time_frame>Day IP-85 through Day MP-365</time_frame>
    <description>High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; PLT: &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; GGT: &gt;2 x ULN; Bilirubin: &gt;2 x ULN; BUN: &gt;2 x BL; Na: &lt;0.95 x LLN/ &gt;1.05 x ULN; K: &lt;0.9 x LLN/ &gt;1.1 x ULN; Ca: &lt;0.8 x LLN/&gt;1.2 x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities</measure>
    <time_frame>Day IP-85 through Day MP-365</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN/ &gt;1.5 x ULN; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Number of Participants With Clinical Response Over Time</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Number of Participants With Clinical Remission Over Time</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL</measure>
    <time_frame>Open-Label Period (Day OL-1 through Day OL-729)</time_frame>
    <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period</measure>
    <time_frame>Last Study Visit (Day OL-729)</time_frame>
    <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Number of Participants With Abatacept-Induced Antibodies</measure>
    <time_frame>For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)</time_frame>
    <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Number of Participants Using Corticosteroids During OL</measure>
    <time_frame>Day OL-1 through Day OL-729</time_frame>
    <description>Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">591</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Abatacept (ABA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg
Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg
1 arm for maintenance period (ABA ~10 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 arm for induction period
1 arm for maintenance period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>abatacept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 arm for open-label extension phase (ABA ~10 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept (ABA)</intervention_name>
    <description>Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).
Induction Period 3 months
Maintenance Period 12 months</description>
    <arm_group_label>Abatacept (ABA)</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Normal saline, IV, 0 mg/kg, every 28 days.
Induction Period 3 months
Maintenance Period 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>~10 mg/kg, once monthly
Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued</description>
    <arm_group_label>abatacept</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 18 years or older

          -  Ulcerative colitis for at lease 3 months

          -  Moderate to severe active ulcerative colitis

          -  Inadequate response or intolerance to standard ulcerative colitis treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Permanente Medical Group, Inc</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western States Clinical Research Inc.</name>
      <address>
        <city>Wheatridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Litchfield County Gastroenterology Assoc.</name>
      <address>
        <city>Torrington</city>
        <state>Connecticut</state>
        <zip>06790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shafran Gasteroenterology Center</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Center</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Research</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology, P.A.</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Gastroenterology And Hepatology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Digestive &amp; Liver Diseases, Inc.</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aga Clinical Research Associates, Llc</name>
      <address>
        <city>Egg Harbor Twp</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Medical Research Llc</name>
      <address>
        <city>Fishkill</city>
        <state>New York</state>
        <zip>12524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Clinical Research</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School Of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good, Larry I.</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Resrch Assoc.</name>
      <address>
        <city>Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastroenterology &amp; Hepatology, Pllc</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanover Medical Specialists, P.A.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Specialists, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants For Clinical Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal &amp; Liver Diseases Consultants</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation For Digestive Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Of The University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Center For Digestive Health</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center Of The Midsouth, P.C.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology Group</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Gastroenterology, Pa</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Clinic Of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Digestive Disease Research Ctr.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065 VIC</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>South Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>42700</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74535</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santo Andre - Sp</city>
        <state>Sao Paulo</state>
        <zip>09060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santos</city>
        <state>Sao Paulo</state>
        <zip>11075</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21941</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3N 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quebec</city>
        <zip>G1L 3L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brno - Bohunice</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682304</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Delhi</city>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hyderabad</city>
        <zip>500058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mangalore</city>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manipal</city>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <zip>400 022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <zip>400 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mysore</city>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 9</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torreon</city>
        <state>Coahuila</state>
        <zip>27250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Df</city>
        <state>Distrito Federal</state>
        <zip>11560</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico, D. F.</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hermosillo</city>
        <state>Sonora</state>
        <zip>83280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-326</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parktown West</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0048</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Overport</city>
        <state>Kwa Zulu Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Belville</city>
        <state>Western Cape</state>
        <zip>7350</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <zip>7506</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>WC1E 6DB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX 39DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <results_first_submitted>August 12, 2010</results_first_submitted>
  <results_first_submitted_qc>November 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2010</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this study, a first cohort (Induction Period First Cohort, IP1C) of 490 participants was randomized and used for analysis of the primary endpoint. Following randomization of IP1C, a second cohort (IP2C) of 146 participants was randomized to provide a sufficient number of participants for the Maintenance Period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Induction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kg</title>
          <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="P2">
          <title>IP1C-ABA ~10 mg/kg</title>
          <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29, and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="P3">
          <title>IP1C-ABA 3 mg/kg</title>
          <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
        </group>
        <group group_id="P4">
          <title>IP1C-Placebo</title>
          <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
        </group>
        <group group_id="P5">
          <title>IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg</title>
          <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="P6">
          <title>IP2C-ABA ~10 mg/kg</title>
          <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29, and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="P7">
          <title>ABA ~10 mg/kg, Maintenance Period (MP)</title>
          <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
        </group>
        <group group_id="P8">
          <title>Placebo, MP</title>
          <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
        </group>
        <group group_id="P9">
          <title>ABA ~10 mg/kg, Open-Label Period (OL)</title>
          <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period (IP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="140"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="29"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject No Longer Meets Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period (MP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="65">At end of IP, 65 participants met response criteria and were randomly assigned to abatacept in MP.</participants>
                <participants group_id="P8" count="66">At end of IP, 66 participants met response criteria and were randomly assigned to placebo in MP.</participants>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="24"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Period (OL)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="349">349 entered OL (those who completed IP but failed response criteria, or completed/relapsed on MP).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="349"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="161"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="145"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
          <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
        </group>
        <group group_id="B2">
          <title>IP1C-ABA ~10 mg/kg</title>
          <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="B3">
          <title>IP1C-ABA 3 mg/kg</title>
          <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
        </group>
        <group group_id="B4">
          <title>IP1C-Placebo</title>
          <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
        </group>
        <group group_id="B5">
          <title>IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg</title>
          <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
        </group>
        <group group_id="B6">
          <title>IP2C-ABA ~10 mg/kg</title>
          <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="140"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="591"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Inadequate Response/Intolerance to Prior Anti-Tumor (TNF) Therapy (Infliximab)</title>
          <description>Prior to this study, participants had an inadequate response and/or intolerance to an approved anti-TNF agent at an approved labeled dose for at least 8 weeks. Inadequate response was assessed by the treating physician and was primarily due to lack of efficacy. Because the treating physician determined prior inadequate response, there was no standard definition for this and criteria for determination may have varied between institutions. Intolerance was defined a an inability to achieve doses or treatment durations because of dose limiting side effects.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Inadequate Response/Intolerant to prior Infliximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Inadequate Response/Intolerance to Infliximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants who were randomized and received at least one infusion of study medication (Intent To Treat Population, ITT) were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
          <population>All participants who were randomized and received at least one infusion of study medication (Intent To Treat Population, ITT) were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis=no treatment difference between ABA arm and placebo (PLA) arm. ABA 30/~10 mg/kg vs PLA: power=98%, sample size=140 per arm,expected PLA response rate=40%, ABA 30/~10 mg/kg=65%. ABA ~10 mg/kg vs. PLA: power=90%, sample size=140 per arm, 5% significance; expected PLA response rate= 40%, ABA ~10=60%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel Chi square p-value and RR along with 95% confidence interval provided, adjusting for randomization strata (whether a participant had an inadequate response and/or intolerance to anti-TNF therapy).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Conditional on ABA 30/~10 mg/kg vs PLA comparison being statistically significant at 5% level, ABA ~10 vs PLA to be tested at 5% significance level.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Baseline Mayo Score: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
        <time_frame>Baseline</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Baseline Mayo Score: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="1.74"/>
                    <measurement group_id="O2" value="8.8" spread="1.73"/>
                    <measurement group_id="O3" value="8.6" spread="1.82"/>
                    <measurement group_id="O4" value="8.8" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis=no treatment difference between each of the ABA and placebo (PLA). At 5% significance level, Aba 30/~10 vs. PLA: power=96%, sample size=140 per arm, expected PLA rate=15%. ABA 30/~10 =35%; Aba ~10 vs. PLA: power=82%, sample size=140 per arm, expected PLA response rate= 15%, ABA/~10 mg/kg=30%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.06</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>Conditional on both the remission comparison for ABA 30/~10 vs PLA, and the clinical response comparison for ABA~10 vs PLA being significant at 5%, the secondary remission comparison for ABA ~10 vs PLA will be tested at 5%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis=no treatment difference (relative risk [RR] of ABA over placebo=1) for mucosal healing. ABA 30/~10 vs. placebo: power=99%, sample size=140 per arm, expected PLA response rate=30%, ABA 30/~10 mg/kg=60%. ABA ~10 vs. placebo: power=98%, sample size=140 per arm, 5% significance; expected PLA response rate= 30%, ABA ~10 mg/kg=55%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Conditional on both the comparison for mucosal healing for ABA 30/~10 vs PLA and the comparison for remission for ABA ~10 vs. PLA being significant, the comparison for mucosal healing for ABA ~10 vs PLA will be tested at 5%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Cochran-Armitage trend test was performed to evaluate whether a relationship existed between the response and dose regimen by comparing the proportion of participants in response across all four treatment arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>All statistical testing was performed at a pre-specified alpha-level of 5%.</p_value_desc>
            <method>Cochran-Armitage Trend Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C</title>
        <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
        <time_frame>Baseline</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C</title>
          <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.0" spread="35.43"/>
                    <measurement group_id="O2" value="121.5" spread="36.42"/>
                    <measurement group_id="O3" value="126.9" spread="35.93"/>
                    <measurement group_id="O4" value="124.3" spread="33.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C</title>
        <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
        <time_frame>Baseline (Day IP-1), Day IP-85 (Week 12)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C</title>
          <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.45" spread="3.514"/>
                    <measurement group_id="O2" value="13.36" spread="3.476"/>
                    <measurement group_id="O3" value="9.87" spread="5.108"/>
                    <measurement group_id="O4" value="23.68" spread="3.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.</description>
        <time_frame>Day IP-85 (Week 12)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rectal Subscore=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal Subscore=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.</description>
        <time_frame>Day IP-85 (Week 12)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stool Frequency Subscore=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool Frequency Subscore=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.</description>
        <time_frame>Day IP-85 (Week 12)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PGA Subscore=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA Subscore=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C</title>
        <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C</title>
          <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Cochran-Armitage trend test was performed to evaluate whether a relationship existed between the response and dose regimen by comparing the proportion of participants in response across all four treatment arms. Normal approximation was used if the number of responses in a treatment group is at least 5. Otherwise an exact method was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <p_value_desc>All statistical testing was performed at a pre-specified alpha-level of 5%</p_value_desc>
            <method>Cochran-Armitage Trend Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</title>
        <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</title>
          <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
        <time_frame>Month 12 (Day MP-365)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</title>
        <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance
=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</title>
          <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance
=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Day OL-1 through the end of the OL</time_frame>
        <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the safety analyses of the Open-Label Extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the safety analyses of the Open-Label Extension phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the safety analyses of the Open-Label Extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the safety analyses of the Open-Label Extension phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-cytomegalovirus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-listeriosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Basal Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Bowen's Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Chronic Myeloid Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Squamous Cell Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-episcleritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-scleritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-anemia hemolytic autoimmune</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Week 12 (Day IP-85)</time_frame>
        <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29,and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>All participants in ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing. Prior inadequate response/intolerance was to an approved anti-TNF agent at an approved labeled dose for ≥8 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
          <group group_id="O5">
            <title>IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O6">
            <title>IP2C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
          <group group_id="O5">
            <title>IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O6">
            <title>IP2C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-candidiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-esophageal candidiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-basal cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-malignant melanoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-uveitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-episcleritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-scleritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-rheumatoid arthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Physical Examination Findings: IP1C + IP2C</title>
        <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>As the results of this study were presented in a synoptic report, physical examination evaluations were not summarized. Laboratory abnormalities and vital signs were collected and summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
          <group group_id="O5">
            <title>IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O6">
            <title>IP2C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Physical Examination Findings: IP1C + IP2C</title>
          <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
          <population>As the results of this study were presented in a synoptic report, physical examination evaluations were not summarized. Laboratory abnormalities and vital signs were collected and summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C</title>
        <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL.</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C</title>
          <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL.</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB; n=136, n=134, n=67, n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit; n=134, n=133, n=67, n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes; n=136, n=134, n=67, n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT; n=136, n=133, n=66, n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT; n=136, n=133, n=66, n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes; n=136, n=134, n=67, n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes; n=136, n=134, n=67, n=133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands; n=136, n=134, n=67, n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils; n=136, n=134, n=67, n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes; n=136, n=134, n=67, n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes; n=136, n=134, n=67, n=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; Sodium (Na): &lt;0.95 x LLN/ &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; calcium (Ca): &lt;0.8 x LLN/&gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; Sodium (Na): &lt;0.95 x LLN/ &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; calcium (Ca): &lt;0.8 x LLN/&gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP, n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN; n=127, n=130, n=62, n=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Na; n=138, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K; n=138, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High K; n=138, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low P; n=137, 135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg,</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>IP1C-Placebo</title>
            <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Glu; n=88, n=91, n=41, n=105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu; n=88, n=91, n=41, n=105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High protein; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin; n=137, n=135, n=66, n=135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein; n=132, n=129, n=66, n=128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine Glu; n=132, n=129, n=66, n=128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood; n=132, n=129, n=66, n=128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase; n=54, n=51, n=27, n=52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC; n=47, n=42, n=17, n=52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC; n=64, n=56, n=27, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C</title>
        <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; Sodium (Na): &lt;0.95 x LLN/ &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN;</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP2C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP2C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C</title>
          <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; Sodium (Na): &lt;0.95 x LLN/ &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN;</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB; n=50, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit; n=50, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes; n=50, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT; n=50, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes; n=50, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes; n=50, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils; n=49, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes; n=49, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes; n=49, n=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN; n=46, n=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Na; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low P; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glu; n=37, n=28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu; n=37, n=28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein; n=50, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine Glu; n=50, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood; n=50, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase; n=21, n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC; n=15, n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC; n=24, n=23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
        <time_frame>Day IP-1 through Day IP-85</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>IP2C-ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP2C-ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Glu; n=37, n=28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu; n=37, n=28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin; n=50, n=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein; n=50, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine Glu; n=50, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood; n=50, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase; n=21, n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC; n=15, n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC; n=24, n=23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C</title>
        <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
        <time_frame>For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85). For participants treated in OL directly after IP: Day IP-1 to Day OL-1. For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)</time_frame>
        <population>All subjects with at least one post-baseline immunogenicity measurement during the study period were included in the immunogenicity data set. &quot;Positive&quot; was defined as &quot;positive post-baseline IP-1&quot; and with a titer value greater than the baseline titer value. Participants with missing baseline titer were assumed &quot;negative&quot; at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>IP1C+IP2C: ABA 30/~10 mg/kg</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>IP1C+IP2C: ABA ~10 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
          <group group_id="O3">
            <title>IP1C-ABA 3 mg/kg</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of 3 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of 3 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C</title>
          <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
          <population>All subjects with at least one post-baseline immunogenicity measurement during the study period were included in the immunogenicity data set. &quot;Positive&quot; was defined as &quot;positive post-baseline IP-1&quot; and with a titer value greater than the baseline titer value. Participants with missing baseline titer were assumed &quot;negative&quot; at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTLA4/Possibly Ig</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ig and/or Ig Junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants in Clinical Remission at Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
        <time_frame>Month 12 (Day MP-365)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants in Clinical Remission at Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
        <time_frame>Month 12 (Day MP-365)</time_frame>
        <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
          <population>All participants in the ITT Population were included in the efficacy analyses. Participants with missing Mayo score were defined as not having achieved clinical response, remission, or mucosal healing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
        <time_frame>Month 6 (Day MP-169), Month 12 (Day MP-365)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants in clinical remission at both Month 6 and Month 12 was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants in clinical remission at both Month 6 and Month 12 was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12</title>
        <description>Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
        <time_frame>Day MP-365 (Month 12)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analyses for corticosteroid sparing were not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12</title>
          <description>Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analyses for corticosteroid sparing were not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Mean Change From Baseline to Month 12 in IBDQ</title>
        <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
        <time_frame>Day MP-365</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis for changes from baseline in IBDQ responses were not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Mean Change From Baseline to Month 12 in IBDQ</title>
          <description>The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis for changes from baseline in IBDQ responses were not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)</title>
        <description>The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).</description>
        <time_frame>Day MP-365</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis for changes from baseline in SF-36 responses were not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)</title>
          <description>The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis for changes from baseline in SF-36 responses were not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12</title>
        <description>Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
        <time_frame>Day MP-365 (Month 12)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analyses for corticosteroid sparing were not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12</title>
          <description>Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analyses for corticosteroid sparing were not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.</description>
        <time_frame>Day MP-365 (Month 12)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants with rectal subscores indicating mild disease (≤1) was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants with rectal subscores indicating mild disease (≤1) was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.</description>
        <time_frame>Day MP-365 (Month 12)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants with stool frequency subscores indicating mild disease (≤1) was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants with stool frequency subscores indicating mild disease (≤1) was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (≤1 Point) at Month 12</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.</description>
        <time_frame>Day MP-365 (Month 12)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants with PGA subscores indicating mild disease (≤1) was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (≤1 Point) at Month 12</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary endpoint analysis to determine the percentage of participants with PGA subscores indicating mild disease (≤1) was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</title>
        <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Month 12 (Day MP-365)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of clinical response in subjects who have had an inadequate response and/or intolerance to anti-TNF therapy was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</title>
          <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of clinical response in subjects who have had an inadequate response and/or intolerance to anti-TNF therapy was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</title>
        <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Month 12 (Day MP-365)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of clinical remission in subjects who have had an inadequate response and/or intolerance to anti-TNF therapy was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</title>
          <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of clinical remission in subjects who have had an inadequate response and/or intolerance to anti-TNF therapy was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
        <time_frame>Month 12 (Day MP-365)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of mucosal healing in subjects who have had an inadequate response and/or intolerance to anti-TNF therapy was not conducted for the MP as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician’s Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of mucosal healing in subjects who have had an inadequate response and/or intolerance to anti-TNF therapy was not conducted for the MP as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Abatacept-Induced Antibodies</title>
        <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
        <time_frame>For participants not entering OL: All measurements starting after Day MP-1 (including follow-up visits). For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1).</time_frame>
        <population>All subjects with at least one post-baseline immunogenicity measurement during the study period were included in the immunogenicity data set. &quot;Positive&quot; was defined as &quot;positive post-baseline IP-1&quot; and with a titer value greater than the baseline titer value. Participants with missing baseline titer were assumed &quot;negative&quot; at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Abatacept-Induced Antibodies</title>
          <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
          <population>All subjects with at least one post-baseline immunogenicity measurement during the study period were included in the immunogenicity data set. &quot;Positive&quot; was defined as &quot;positive post-baseline IP-1&quot; and with a titer value greater than the baseline titer value. Participants with missing baseline titer were assumed &quot;negative&quot; at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTLA4/Possibly Ig</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ig and/or Ig Junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Day MP-1 through Day MP-365</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
        <time_frame>Day MP-1 through Day MP-365</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic Infections-pneumonia herpes viral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies-breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-erythema nodosum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders-pemphigoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Physical Examination Findings</title>
        <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
        <time_frame>Day IP-85 through Day MP-365</time_frame>
        <population>As the results of this study were presented in a synoptic report, physical examination evaluations were not summarized. Laboratory abnormalities and vital signs were collected and summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Physical Examination Findings</title>
          <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
          <population>As the results of this study were presented in a synoptic report, physical examination evaluations were not summarized. Laboratory abnormalities and vital signs were collected and summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Marked Hematology Laboratory Abnormalities</title>
        <description>High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; PLT: &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; GGT: &gt;2 x ULN; Bilirubin: &gt;2 x ULN; BUN: &gt;2 x BL; Na: &lt;0.95 x LLN/ &gt;1.05 x ULN; K: &lt;0.9 x LLN/ &gt;1.1 x ULN; Ca: &lt;0.8 x LLN/&gt;1.2 x ULN</description>
        <time_frame>Day IP-85 through Day MP-365</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA 30/~10 mg/kg, MP</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Marked Hematology Laboratory Abnormalities</title>
          <description>High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; PLT: &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; GGT: &gt;2 x ULN; Bilirubin: &gt;2 x ULN; BUN: &gt;2 x BL; Na: &lt;0.95 x LLN/ &gt;1.05 x ULN; K: &lt;0.9 x LLN/ &gt;1.1 x ULN; Ca: &lt;0.8 x LLN/&gt;1.2 x ULN</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB; n=64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes; n=64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT; n= 64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High lymphocytes; n=64, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT; n=64, n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High bilirubin, n=64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN; n=57, n=59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Na; n=64, n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K; n=64, n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca; n=64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glu; n=45, n=38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu; n=45, n=38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein; n=64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein; n=58, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine Glu; n=58, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood; n=58, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase; n=23, n=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC; n=24, n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC; n=29, n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN/ &gt;1.5 x ULN; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
        <time_frame>Day IP-85 through Day MP-365</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA 30/~10 mg/kg, MP</title>
            <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). Following this, on Days IP-29 and IP-57 abatacept was administered IV at a dose of ~10 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN/ &gt;1.5 x ULN; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Glu; n=45, n=38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu; n=45, n=38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein; n=64, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein; n=58, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine Glu; n=58, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood; n=58, n=58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase; n=23, n=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC; n=24, n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC; n=29, n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Physical Examination Findings</title>
        <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>As the results of this study were presented in a synoptic report, physical examination evaluations were not summarized. Laboratory abnormalities and vital signs were collected and summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Physical Examination Findings</title>
          <description>Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).</description>
          <population>As the results of this study were presented in a synoptic report, physical examination evaluations were not summarized. Laboratory abnormalities and vital signs were collected and summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Number of Participants With Clinical Response Over Time</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the efficacy analyses of the OL. Number of Participants Analyzed=all participants in OL; n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Clinical Response Over Time</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.</description>
          <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the efficacy analyses of the OL. Number of Participants Analyzed=all participants in OL; n=number of evaluable participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day OL-365 (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day OL-729 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Number of Participants With Clinical Remission Over Time</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the efficacy analyses of the OL. Number of Participants Analyzed=all participants in OL; n=number of evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Clinical Remission Over Time</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.</description>
          <population>All participants who received at least 1 infusion of open-label study medication at any time were included in the efficacy analyses of the OL. Number of Participants Analyzed=all participants in OL; n=number of evaluable participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day OL-365 (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day OL-729 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Marked Hematology Laboratory Abnormalities</title>
        <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL.</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Marked Hematology Laboratory Abnormalities</title>
          <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL.</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB; n=326</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit; n=322</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes; n=326</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT; n=323</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes; n=326</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes; n=326</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands; n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils; n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes; n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes; n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; calcium (Ca): &lt;0.8 x LLN/&gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; potassium (K): &lt;0.9 x LLN/ &gt;1.1 x ULN; calcium (Ca): &lt;0.8 x LLN/&gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN/ &gt;1.2 5 x ULN</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP, n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST, n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT; n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT; n=332</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High bilirubin, n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN; n=310</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine; n=330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low K; n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca; n=330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low P; n=330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High P, n=330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN/ &gt;1.5 x ULN; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During IP, abatacept was administered IV on Days IP-1 and IP-15 at a dose of ~10 mg/kg (weight-tiered). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): &lt;65 mg/dL/ &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN/ &gt;1.5 x ULN; total protein: &lt; 0.9 x LLN/ &gt;1.1 x ULN; albumin:&lt;0.9 x LLN; uric acid: &gt;1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells [RBCs], White Blood Cells [WBCs]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3</description>
          <population>The As Treated analysis population was used for all safety summaries and was defined to include all participants who received at least one infusion of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Glu; n=245</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glu; n=245</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low protein; n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin; n=331</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine protein; n=312</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine Glu; n=312</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine blood; n=312</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocyte esterase; n=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine RBC; n=115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High urine WBC; n=150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL</title>
        <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
        <time_frame>Open-Label Period (Day OL-1 through Day OL-729)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of mucosal healing was not conducted for the OL as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, MP</title>
            <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, MP</title>
            <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL</title>
          <description>The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of mucosal healing was not conducted for the OL as planned.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period</title>
        <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>Last Study Visit (Day OL-729)</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of clinical efficacy upon retreatment with abatacept among participants who received study drug during the IP or MP was not conducted for the OL as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period</title>
          <description>The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of clinical efficacy upon retreatment with abatacept among participants who received study drug during the IP or MP was not conducted for the OL as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Number of Participants With Abatacept-Induced Antibodies</title>
        <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
        <time_frame>For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)</time_frame>
        <population>All subjects with at least one post-baseline immunogenicity measurement during the study period were included in the immunogenicity data set. &quot;Positive&quot; was defined as &quot;positive post-baseline IP-1&quot; and with a titer value greater than the baseline titer value. Participants with missing baseline titer were assumed &quot;negative&quot; at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Abatacept-Induced Antibodies</title>
          <description>A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
          <population>All subjects with at least one post-baseline immunogenicity measurement during the study period were included in the immunogenicity data set. &quot;Positive&quot; was defined as &quot;positive post-baseline IP-1&quot; and with a titer value greater than the baseline titer value. Participants with missing baseline titer were assumed &quot;negative&quot; at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTLA4/Possibly Ig</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ig and/or Ig Junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Number of Participants Using Corticosteroids During OL</title>
        <description>Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.</description>
        <time_frame>Day OL-1 through Day OL-729</time_frame>
        <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of corticosteroid use was not conducted for the OL as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA ~10 mg/kg, OL</title>
            <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants Using Corticosteroids During OL</title>
          <description>Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.</description>
          <population>Due to the early termination of the study after preliminary IP1C results were reviewed and the primary efficacy endpoint was not achieved, the secondary subgroup analyses of corticosteroid use was not conducted for the OL as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ABA 30/~10 mg/kg,IP1C</title>
          <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="E2">
          <title>ABA 30/~10mg/kg,IP2C</title>
          <description>During IP, abatacept was administered intravenously (IV) on Days IP-1 and IP-15 at a dose of 30 mg/kg (fixed dose). On Days IP-29 and IP-57, abatacept was administered IV at a dose of ~10 mg/kg.</description>
        </group>
        <group group_id="E3">
          <title>ABA 3 mg/kg,IP1C</title>
          <description>During IP, abatacept was administered IV on Days IP-1, IP-15, IP-29, and IP-57 at a dose of 3 mg/kg (fixed dose).</description>
        </group>
        <group group_id="E4">
          <title>ABA ~10 mg/kg,IP1C</title>
          <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29, and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="E5">
          <title>ABA ~10mg/kg,IP2C</title>
          <description>During IP, abatacept was administered IV on Days IP-1,IP-15, IP-29, and IP-57 at a dose of ~10 mg/kg (weight-tiered).</description>
        </group>
        <group group_id="E6">
          <title>ABA ~10mg/kg, MP</title>
          <description>During MP, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day MP-1.</description>
        </group>
        <group group_id="E7">
          <title>ABA ~10 mg/kg, OL</title>
          <description>During OL, abatacept was administered IV at a dose of ~10 mg/kg (weight-tiered) every 28 days beginning Day OL-1.</description>
        </group>
        <group group_id="E8">
          <title>Placebo, IP1C</title>
          <description>During the IP, placebo was administered IV on Days IP-1, IP-15, IP-29, and IP-57.</description>
        </group>
        <group group_id="E9">
          <title>Placebo, MP</title>
          <description>During the MP, placebo was administered IV every 28 days beginning Day MP-1 through Day MP-337.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="66" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>VIRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>LISTERIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PELVIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PNEUMONIA HERPES VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>FIBROMYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PERSONALITY CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PYODERMA GANGRENOSUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="137" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="45" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated after review of the IP1C results due to lack of efficacy. Enrollment for the MP and for IP2C was not completed. Participants in MP, IP2C, and OL were early terminated at the time of study termination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

